General
Preferred name
profenamine
Synonyms
ETHOPROPAZINE HYDROCHLORIDE ()
Profenamine hydrochloride ()
ETHOPROPAZINE ()
Ethopropazine (hydrochloride) ()
Isothazine ()
Isothazine (hydrochloride) ()
Lysivane (hydrochloride) ()
Parsidol (hydrochloride) ()
Ethopropazine hcl ()
NSC-169467 ()
Parsidol ()
NSC-64074 ()
SC-2538 ()
RP-3356 ()
Profenamina ()
W-483 ()
P&D ID
PD010074
CAS
1094-08-2
522-00-9
42957-54-0
Tags
available
drug
Approved by
FDA
Drug indication
Parkinson disease
Drug Status
approved
withdrawn
Max Phase
4.0
First approval
1982
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Ethopropazine (Isothazine) hydrochloride is a potent, selective BChE inhibitor and a poor AChE inhibitor. Ethopropazine hydrochloride is a phenothiazine compound with anticholinergic properties. Ethopropazine hydrochloride can be used for the research of Parkinson¡¯s disease[1][2].
PRICE 35
DESCRIPTION Ethopropazine Hydrochloride is the salt form of Ethopropazine (Profenamine), a phenothiazine derivative with anticholinergic, antihistamine, and anti-adrenergic effects used in the treatment of Parkinson's disease, and acts as an AChE inhibitor by affecting the PAS active site.
DESCRIPTION Ethopropazine is a phenothiazine derivative drug. (GtoPdb)
DESCRIPTION Butyrylcholinesterase inhibitor; antiparkinsonian (LOPAC library)
DESCRIPTION Ethopropazine hydrochloride is an inhibitor of butyrylcholinesterase. It is a medication derived from phenothiazine. It could reduce extrapyramidal motor effects and used as an antidyskinetic to treat Parkinson's disease. It also alleviates thermal hyperalgesia in rats. It is sold under the trade names Parsidol in the United States and Parsidan in Canada. It was developed by Pfizer and has been listed. (BOC Sciences Bioactive Compounds)
Cell lines
0
Organisms
1
Compound Sets
22
BOC Sciences Bioactive Compounds
ethopropazine-hydrochloride-cas-1094-08-2-item-160456
Cayman Chemical Bioactives
28493
ChEMBL Approved Drugs
CHEMBL1200970
CHEMBL1206
ChEMBL Drugs
CHEMBL1200970
CHEMBL1206
DrugBank
DB00392
DrugBank Approved Drugs
DB00392
DrugCentral
1086
DrugCentral Approved Drugs
1086
DrugMAP
DM0N3L7
DrugMAP Approved Drugs
DM0N3L7
DrugMatrix
Guide to Pharmacology
7181
Ki Database
ethopropazine
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1206
MedChem Express Bioactive Compound Library
HY-107922
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
The Spectrum Collection
Withdrawn 2.0
140
External IDs
45
Properties
(calculated by RDKit )
Molecular Weight
312.17
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
0
Rotatable Bonds
5
Ring Count
3
Aromatic Ring Count
2
cLogP
5.02
TPSA
6.48
Fraction CSP3
0.37
Chiral centers
1.0
Largest ring
6.0
QED
0.77
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Selectivity
Butyrylcholinesterase
Member status
member
MOA
NMDA Antagonists
Butyrylcholinesterase Inhibitors
ATC
N04AA05
Therapeutic Class
Antiparkinson Agents
Pathway
GPCR/G protein
Membrane Transporter/Ion Channel
Neuronal Signaling
Solubility
DMSO: >5 mg/mL at ~60 °C, clear
Target
Cholinesterase (ChE)
iGluR
mAChR
Source data